Dateline City:
PHILADELPHIA
KEYTRUDA Demonstrated 28 Percent Overall Response Rate and 76 Percent Disease Control Rate in Difficult-to-Treat Cancer
First Findings from KEYNOTE-028, Mercks Innovative Basket Trial in 20 Cancers
PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first presentation of data investigating the use of
KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy,
in 25 patients with advanced pleural mesothelioma, a difficult-to-treat
cancer of the lining of the lungs, abdomen and other organs. The early
findings presented showed an overall response rate (confirmed and
unconfirmed) of 28 percent with KEYTRUDA in patients with tumors that
expressed PD-L1.
Language:
English
Contact:
Media:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more